Celldex Therapeutics Inc
$ 33.33
2.27%
14 Apr - close price
- Market Cap 2,615,175,000 USD
- Current Price $ 33.33
- High / Low $ 33.72 / 31.96
- Stock P/E N/A
- Book Value 7.92
- EPS -3.90
- Next Earning Report 2026-05-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.26 %
- ROE -0.41 %
- 52 Week High 34.52
- 52 Week Low 17.45
About
Celldex Therapeutics, Inc., a biopharmaceutical company, is dedicated to the development of therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. The company is headquartered in Hampton, New Jersey.
Analyst Target Price
$54.33
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-02 | 2025-11-10 | 2025-08-07 | 2025-05-05 | 2025-02-24 | 2024-10-31 | 2024-08-08 | 2024-05-06 | 2024-02-26 | 2023-11-02 | 2023-08-08 | 2023-05-04 |
| Reported EPS | -1.22 | -1.01 | -0.85 | -0.81 | -0.71 | -0.64 | -0.54 | -0.56 | -0.83 | -0.81 | -0.65 | -0.62 |
| Estimated EPS | -1 | -0.9 | -0.86 | -0.69 | -0.7146 | -0.67 | -0.59 | -0.69 | -0.74 | -0.68 | -0.67 | -0.63 |
| Surprise | -0.22 | -0.11 | 0.01 | -0.12 | 0.0046 | 0.03 | 0.05 | 0.13 | -0.09 | -0.13 | 0.02 | 0.01 |
| Surprise Percentage | -22% | -12.2222% | 1.1628% | -17.3913% | 0.6437% | 4.4776% | 8.4746% | 18.8406% | -12.1622% | -19.1176% | 2.9851% | 1.5873% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-14 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -1.1 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CLDX
2026-04-13 20:09:57
Celldex (NASDAQ: CLDX) announced that its management will participate in a fireside chat at H.C. Wainwright’s 4th Annual Inflammatory Skin Disease Virtual Conference on April 14, 2026, at 3:30 pm ET. A live webcast of the presentation will be available on the company's Investors section, with replays accessible for 90 days. The event will focus on developments in inflammatory skin diseases.
2026-04-09 11:40:04
Celldex Therapeutics recently raised $345 million through an equity offering and released new Phase 2 barzolvolimab data. Despite its current P/B ratio appearing in line with peers, a discounted cash flow model suggests the stock might be significantly undervalued. The article advises investors to assess the company's valuation, considering both potential rewards and warning signs.
2026-04-09 03:24:00
This article provides a detailed analysis of Celldex Therapeutics Inc. (CLDX), highlighting a near-term neutral sentiment amidst mid and long-term strength. It outlines various AI-generated trading strategies, including position, momentum breakout, and risk hedging, complete with entry, target, and stop-loss zones. The analysis also covers multi-timeframe signal strengths, support, and resistance levels for effective precision trading.
2026-04-07 07:39:46
Celldex Therapeutics, a clinical-stage biotech company, has closed a $345 million public stock offering, including the full exercise of the underwriters' option to purchase additional shares. The company sold nearly 12 million shares at $29 each, resulting in gross proceeds of approximately $345 million. Celldex plans to use these funds to advance its pipeline of antibody-based treatments for severe inflammatory, allergic, and autoimmune diseases, demonstrating investor confidence in its immune-based therapies.
2026-04-06 23:39:17
Celldex Therapeutics announced the closing of its underwritten public offering of 11,896,750 shares of common stock, including the full exercise of the underwriters' option to purchase additional shares, at $29.00 per share. The offering generated gross proceeds of approximately $345 million for Celldex. Leerink Partners, TD Cowen, Guggenheim Securities, and Cantor served as joint bookrunning managers.
2026-04-06 15:10:25
Celldex Therapeutics announced the closing of its underwritten public offering, selling 11,896,750 common shares, including the full exercise of the underwriters' option for additional shares. The sale, priced at $29.00 per share, generated approximately $345 million in gross proceeds for the company. This financing operation finalizes a capital raise process that began in early April 2026.
